Loading company…
Synakis develops biomaterial treatments for retinal and other ocular diseases.
Founded in 2019 and based in Toronto, Canada, Synakis develops biomaterial-based treatments for ocular diseases. Its SNK-125 hydrogel is designed for ocular delivery in retinal surgery and conditions such as retinal detachment and glaucoma. In May 2026, it raised CAD 2.6 million in pre-seed funding co-led by TIAP and Chiefswood Private Capital Inc. to advance preclinical studies and regulatory submissions.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in